Search
T487
go.drugbank.com/drugs/DB05474ExperimentalT487 is a small molecule chemokine receptor antagonist to correct or modify immune system responses. It binds selectively and potently to CXCR3. … The formulation is administered orally and has anti-inflammatory effects in conditions such as rheumatoid arthritis, inflammatory bowel disease and psoriasis.
Descartes-30
go.drugbank.com/drugs/DB16361Investigational[L27531] The RNA-engineering is performed with Cartesian Therapeutics’ proprietary RNA Armory which is a platform that activates and provides cells with mRNA-based therapeutics. … Descartes-30 is an RNA-engineered off-the-shelf allogeneic mesenchymal stem cell (MSC) product developed by Cartesian Therapeutics.
Merimepodib
go.drugbank.com/drugs/DB04862InvestigationalMerimepodib (VX-497) is a novel noncompetitive inhibitor of IMPDH. … Merimepodib is orally bioavailable and inhibits the proliferation of primary human, mouse, rat, and dog lymphocytes at concentrations of approximately 100 nM.
DLO6002
go.drugbank.com/drugs/DB05179ExperimentalDLO6002 is developed by Summit Corporation and is in phase I of clinical trials for the treatment of Parkinson's disease.
Gantacurium
go.drugbank.com/drugs/DB05710InvestigationalGantacurium chloride is a new, investigational, non-depolarizing ultra-short acting neuromuscular blocker. It is being developed by Avera Pharmaceuticals.
Mimopezil
go.drugbank.com/drugs/DB05520ExperimentalMimopezil is a pro-drug that is rapidly absorbed and converted into huperzine A. … Mimopezil is an acetylcholinesterase (AChE) inhibitor that has demonstrated potential use in the treatment of Alzheimer's disease.
Davunetide
go.drugbank.com/drugs/DB12613InvestigationalDavunetide is the first drug to improve memory performance by impacting the mechanisms that lead to physical damage in the brain caused by neurofibrillary tangles, one of the two established pathological … Davunetide is derived from a naturally occurring neuroprotective brain protein known as activity dependent neuroprotective protein.
ALKS 29
go.drugbank.com/drugs/DB05723ExperimentalALKS 29 is a new product candidate for the treatment of alcohol dependence. It is being developed by Alkermes, Inc.
VB2-011
go.drugbank.com/drugs/DB05411ExperimentalVB2-011 is an antibody developed as an anti-cancer treatment. According to some preclinical studies, it has a potential to inhibit tumour growth in various cancers including lymphoma and melanoma.
Azidocillin
go.drugbank.com/drugs/DB08795ExperimentalAzidocillin is a penicillin antibiotic similir to ampicillin.